The Medicines Co.’s Cangrelor Rises From The Ashes Of Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
TMC reported successful top-line data from its Phase III PHOENIX study of its anticlotting drug cangrelor and expects to file an NDA this year.
You may also be interested in...
The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
After two failed studies, The Medicines Co.’s rapid-acting I.V. antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.
The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
After two failed studies, The Medicines Co.’s rapid-acting IV antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.
The Medicines Co. Plans Mid-2013 Regulatory Submissions For Two Key R&D Assets
The Medicines Co is capitalizing on trends prevalent in both the biopharma industry and its customer base to build one of the fastest- growing specialty pharma franchises. Results for 2012 confirm the strategy has worked to date.